Cardiac complications after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab

Bone Marrow Transplantation

Volumn 36, Issue 9, 2005, Pages 821-824

  Oshima, K ^a   Sakata Yanagimoto, M ^a   Asano Mori, Y ^a   Izutsu, K ^a   Watanabe, T ^a   Shoda, E ^a   Ogawa, S ^a   Motokura, T ^a   Chiba, S ^a   Kurokawa, M ^a   Hirai, H ^a   Kanda, Y ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

Alemtuzumab; Cardiac complications; Hematopoietic stem cell transplantation; HLA mismatch

Indexed keywords

ALEMTUZUMAB; ANTHRACYCLINE; BUSULFAN; CATECHOLAMINE DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIURETIC AGENT; ETOPOSIDE; FLUDARABINE; METHOTREXATE; METHYLPREDNISOLONE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DRUG USE; FEMALE; HEART DISEASE; HLA MATCHING; HUMAN; IN VIVO STUDY; INCIDENCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STOMATITIS; WHOLE BODY RADIATION;

ADULT; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CASE-CONTROL STUDIES; CATECHOLAMINES; DIURETICS; DRUG EVALUATION; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEART DISEASES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 27744600591     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705145     Document Type: Article

References (18)

1. Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001; 3: 137-143.
2. Chakraverty R, Peggs K, Chopra R et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071-1078.
3. Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419-2425.
4. Faulkner RD, Craddock C, Byrne JL et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004; 103: 428-434.
5. Ho AY, Pagliuca A, Kenyon M et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004; 104: 1616-1623.
6. Peggs KS, Mackinnon S, Williams CD et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: Limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 2003; 9: 257-265.
7. Kanda Y, Oshima K, Asano-Mori Y et al. In vivo alemtuzumab enables haploidentical HLA-mismatched hematopoietic stem cell transplantation without ex vivo graft manipulation. Transplantation 2005; 79: 1351-1357.
8. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
9. Sakata-Yanagimoto M, Kanda Y, Nakagawa M et al. Predictors for severe cardiac complications after hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 33: 1043-1047.
10. Ferrajoli A, O'Brien SM, Cortes JE et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003; 98: 773-778.
11. Kennedy GA, Seymour JF, Wolf M et al. Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur J Haematol 2003; 71: 250-256.
12. Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001; 98: 1721-1726.
13. Pawson R, Dyer MJ, Barge R et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997; 15: 2667-2672.
14. Lenihan DJ, Alencar AJ, Yang D et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 2004; 104: 655-658.
15. Mann DL. Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circ Res 2002; 91: 988-998.
16. Blum A, Miller H. Pathophysiological role of cytokines in congestive heart failure. Annu Rev Med 2001; 52: 15-27.
17. Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 893-898.
18. Niwa N, Watanabe E, Hamaguchi M et al. Early and late elevation of plasma atrial and brain natriuretic peptides in patients after bone marrow transplantation. Ann Hematol 2001; 80: 460-465.